The role of circulating miRNAs and CA19-9 in pancreatic cancer diagnosis

Nivaldo Faria Vieira,Luciano Neder Serafini,Paulo Cezar Novais,Fermino Sanches Lizarte Neto,Mucio Luiz de Assis Cirino,Rafael Kemp,José Celso Ardengh,Fabiano Pinto Saggioro,Alberto Facury Gaspar,Ajith Kumar Sankarankutty,Jorge Resende Lopes Júnior,Daniela Pretti da Cunha Tirapelli,José Sebastião dos Santos
DOI: https://doi.org/10.18632/oncotarget.28038
2021-08-17
Oncotarget
Abstract:Diagnosis and treatment of pancreatic ductal adenocarcinoma (PA) remains a challenge in clinical practice. The aim of this study was to assess the role of microRNAs (miRNAs-21, -23a, -100, -107, -181c, -210) in plasma and tissue as possible biomarkers in the diagnosis of PA. Samples of plasma (PAp-n = 13), pancreatic tumors (PAt-n = 18), peritumoral regions (PPT-n = 9) were collected from patients during the surgical procedure. The control group consisted of samples from patients submitted to pancreatic surgery for trauma or cadaveric organs (PC-n = 7) and healthy volunteers donated blood (PCp-n = 6). The expression profile of microRNAs was measured in all groups using RT-PCR, serum CA19-9 levels were determined in PA and PC. In tissue samples, there was a difference in the expression of miRNAs-21, -210 (<i>p</i> &lt; 0.05) across the PAt, PC and PPT groups. The PAp showed overexpression of miRNAs-181c, -210 (<i>p</i> &lt; 0.05) when compared to PCp. The combination of miRNAs-21, -210 tissue expression and serum CA19-9 showed 100% accuracy in the diagnosis of PA, as well as miR-181c expression in the plasma (PApxPCp). The expression of microRNAs in plasma proved to be a promising tool for a noninvasive detection test for PA, as well as further studies will evaluate the utility of microRNAs expression as biomarkers for prognostic and response to therapy in PA.
What problem does this paper attempt to address?